The Spanish workgroup for the pharmaceutical care of neurological conditions (GEAFEN) was established in 2018 as a spin-off of the MAPEX initiative and as a response to SEFH’s superspecialization strategy.
The treatment of neurological conditions such as multiple sclerosis, Parkinson’s disease, lateral amyotrophic sclerosis (LAS), and myasthenia gravis, among others, involves managing highly complex patients. The sheer complexity of these conditions requires hospital pharmacists to significantly expand their breadth of knowledge.
The workgroup seeks to promote the continuous improvement of the care provided to these patients, promoting full integration of the pharmacist into their hospital’s multidisciplinary care teams; to develop expert patient programs; to build stronger relationships with patient associations; and to work on new educational programs, the evaluation of new drugs and the promotion of research.